New injection shows promise for Tough-to-Treat blood cancer
Disease control
Recruiting now
This early-phase study tests a new injection called JY232 in 9 people with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose. Researchers will also look at how well the injection controls the cancer,…
Phase: EARLY_PHASE1 • Sponsor: Shenzhen Genocury Biotech Co., Ltd. • Aim: Disease control
Last updated May 03, 2026 10:39 UTC